249420.KS
Ildong Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 12,570.00
−1.72%Year over year
Reported trailing growth
- Revenue
- -0.7%
- EBITDA
- —
- EBIT
- +49.3%
- EPS
- +1696.7%
- Free cash flow
- —
- Operating cash flow
- +118.3%
Forward estimates
Based on analyst estimates
- Revenue
- +10.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.8%
- EBITDA
- +18.8%
- EBIT
- +32.0%
- Net income
- +704.5%
- EPS
- +675.7%
- Free cash flow
- -62.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026